Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Three firms in EU get nods on pegfilgrastim

Executive Summary

Three firms – Mundipharma, Mylan and Sandoz – have received final pan-European marketing authorisations from the European Commission for biosimilar rivals toAmgen’s Neulasta (pegfilgrastim). The nods for Mundipharma’s Pelmeg, Mylan’s Fulphila and Sandoz’ Ziextenzo followed positive recommendations from the European Medicines Agency’s (EMA’s) committee for human medicinal products (CHMP) towards the end of September (Generics bulletin, 28 September 2018, page 15).

You may also be interested in...

Mundipharma And Egis Partner For Pelmeg In Four CEE Markets

Mundipharma is entering into a partnership with Egis for launching its pegfilgrastim biosimilar treatment in Hungary, Romania, Latvia and Lithuania.

USV’s Juta Gets An EU Pegfilgrastim Nod

Juta Pharma has received a positive opinion from the European Medicines Agency’s CHMP recommending granting a pan-European marketing authorization for its biosimilar pegfilgrastim, Grasustek.

Sandoz Tries Again With US Pegfilgrastim

Sandoz has resubmitted its application for biosimilar pegfilgrastim to the FDA, having been knocked back with a complete response letter in 2016.

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts